Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 465715, 10 pages
http://dx.doi.org/10.1155/2008/465715
Research Article

Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR- 𝛾 Agonist

1Research and Preclinical Development, Metabolex, Inc., 3876 Bay Center Place, Hayward, CA 94545, USA
2Department of Molecular Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Received 25 March 2008; Accepted 15 July 2008

Academic Editor: Anne Miller

Copyright © 2008 Holly J. Clarke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Aronow, P. R. Harding, M. Khursheed, J. S. Vangrow, and N. P. Papageorge's, “Effect of halofenate on serum uric acid,” Clinical Pharmacology & Therapeutics, vol. 14, no. 3, pp. 371–373, 1973. View at Google Scholar
  2. W. S. Aronow, P. R. Harding, M. Khursheed, J. S. Vangrow, N. P. Papageorge's, and J. Mays, “Effect of halofenate on serum lipids,” Clinical Pharmacology & Therapeutics, vol. 14, no. 3, pp. 358–365, 1973. View at Google Scholar
  3. W. S. Aronow, J. Vangrow, J. Pagano, M. Khemka, M. Vawter, and N. P. Papageorge's, “Long-term effect of halofenate on serum lipids,” Current Therapeutic Research: Clinical and Experimental, vol. 16, no. 9, pp. 897–903, 1974. View at Google Scholar
  4. W. S. Aronow, J. S. Vangrow, W. H. Nelson et al., “Halofenate: an effective hypolipemia- and hypouricemia-inducing drug,” Current Therapeutic Research: Clinical and Experimental, vol. 15, no. 12, pp. 902–906, 1973. View at Google Scholar
  5. W. S. Aronow, M. D. Vicario, K. Moorthy, J. King, M. Vawter, and N. P. Papageorge's, “Long-term efficacy of halofenate on serum triglyceride levels,” Current Therapeutic Research: Clinical and Experimental, vol. 18, no. 6, pp. 855–861, 1975. View at Google Scholar
  6. C. A. Dujovne, D. L. Azarnoff, P. Pentikainen, C. Manion, A. Hurwitz, and K. Hassanein, “A two-year crossover therapeutic trial with halofenate and clofibrate,” The American Journal of the Medical Sciences, vol. 272, no. 3, pp. 277–284, 1976. View at Publisher · View at Google Scholar
  7. E. B. Feldman, F. B. Gluck, and A. C. Carter, “Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia,” The Journal of Clinical Pharmacology, vol. 18, no. 5-6, pp. 241–248, 1978. View at Google Scholar
  8. L. H. Krut, H. C. Seftel, and B. I. Joffe, “Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia,” South African Medical Journal, vol. 51, no. 11, pp. 348–352, 1977. View at Google Scholar
  9. A. K. Jain, J. R. Ryan, and F. G. McMahon, “Potentiation of hypoglycemic effect of sulfonylureas by halofenate,” The New England Journal of Medicine, vol. 293, no. 25, pp. 1283–1286, 1975. View at Google Scholar
  10. E. A. Kohl, J. A. Magner, S. T. Persellin, G. M. Vaughan, D. J. Kudzma, and S. J. Friedberg, “Improved control of non-insulin-dependent diabetes mellitus by combined halofenate and chlorpropamide therapy,” Diabetes Care, vol. 7, no. 1, pp. 19–24, 1984. View at Publisher · View at Google Scholar
  11. D. J. Kudzma and S. J. Friedberg, “Potentiation of hypoglycemic effect of chlorpropamide and phenformin by halofenate,” Diabetes, vol. 26, no. 4, pp. 291–295, 1977. View at Publisher · View at Google Scholar
  12. T. Allen, F. Zhang, S. A. Moodie et al., “Halofenate is a selective peroxisome proliferator-activated receptor γ modulator with antidiabetic activity,” Diabetes, vol. 55, no. 9, pp. 2523–2533, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. F. Zhang, B. E. Lavan, and F. M. Gregoire, “Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects,” PPAR Research, vol. 2007, Article ID 32696, 7 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. P. A. Krieter, A. E. Colletti, G. A. Doss, and R. R. Miller, “Disposition and metabolism of the hypoglycemic agent pioglitazone in rats,” Drug Metabolism and Disposition, vol. 22, no. 4, pp. 625–630, 1994. View at Google Scholar
  15. Z. J. Lin, D. Desai-Krieger, and L. Shum, “Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 801, no. 2, pp. 265–272, 2004. View at Publisher · View at Google Scholar
  16. P. Yi, C. E. Hadden, W. F. Annes et al., “The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor α-γ dual, γ-dominant agonist in mice, rats, and monkeys,” Drug Metabolism and Disposition, vol. 35, no. 1, pp. 51–61, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. M. D. Greenspan, J. I. Germershausen, and R. Mackow, “Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes,” Biochimica et Biophysica Acta, vol. 380, no. 2, pp. 190–198, 1975. View at Google Scholar
  18. W. D. Wosilait and P. Nagy, “The distribution of halofenate in plasma: a comparative analysis using Scatchard vs. stepwise association constants,” Research Communications in Chemical Pathology and Pharmacology, vol. 14, no. 1, pp. 75–81, 1976. View at Google Scholar
  19. R. L. Rich, Y. S. N. Day, T. A. Morton, and D. G. Myszka, “High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE,” Analytical Biochemistry, vol. 296, no. 2, pp. 197–207, 2001. View at Publisher · View at Google Scholar · View at PubMed
  20. Y. S. N. Day and D. G. Myszka, “Characterizing a drug's primary binding site on albumin,” Journal of Pharmaceutical Sciences, vol. 92, no. 2, pp. 333–343, 2003. View at Publisher · View at Google Scholar · View at PubMed
  21. J. M. Collins and R. W. Klecker, Jr., “Evaluation of highly bound drugs: interspecies, intersubject, and related comparisons,” The Journal of Clinical Pharmacology, vol. 42, no. 9, pp. 971–975, 2002. View at Google Scholar